Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

What really happens after you hit enter on that AI prompt? WSJ’s Joanna Stern heads inside a data center to trace the journey and then grills up some steaks to show just how much energy it takes to ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

Fivetran, a global leader in automated data movement, is releasing the Oracle Binary Log Reader, a new replication method within its managed service that enables high-volume, low-latency replication ...

A controlled test compared three nearly identical pages: one with strong schema, one with poor schema, and one with none. Only the page with well-implemented schema appeared in an AI Overview and ...

Section 1. Policy and Purpose. My Administration has inaugurated a golden age for American manufacturing and technological dominance. We will pursue bold, large-scale industrial plans to vault the ...

Spending time as wee hackers perusing the family atlas taught us an appreciation for a good map, and [Billy Roberts], a cartographer at NREL, has served up a doozy with a map of the data center ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...